693 related articles for article (PubMed ID: 32881593)
21. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
22. Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19.
Pillat MM; Krüger A; Guimarães LMF; Lameu C; de Souza EE; Wrenger C; Ulrich H
Cytometry A; 2020 Sep; 97(9):872-881. PubMed ID: 32686260
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
Marmor MF
Am J Ophthalmol; 2020 Aug; 216():A1-A2. PubMed ID: 32439074
[No Abstract] [Full Text] [Related]
24. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
Satlin MJ; Goyal P; Magleby R; Maldarelli GA; Pham K; Kondo M; Schenck EJ; Rennert H; Westblade LF; Choi JJ; Safford MM; Gulick RM
PLoS One; 2020; 15(7):e0236778. PubMed ID: 32701969
[TBL] [Abstract][Full Text] [Related]
25. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
Gao J; Hu S
Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
[TBL] [Abstract][Full Text] [Related]
26. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Lei ZN; Wu ZX; Dong S; Yang DH; Zhang L; Ke Z; Zou C; Chen ZS
Pharmacol Ther; 2020 Dec; 216():107672. PubMed ID: 32910933
[TBL] [Abstract][Full Text] [Related]
27. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Li C; Cheng G
Front Immunol; 2020; 11():1969. PubMed ID: 32849658
[TBL] [Abstract][Full Text] [Related]
28. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
[TBL] [Abstract][Full Text] [Related]
29. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.
Ruamviboonsuk P; Lai TYY; Chang A; Lai CC; Mieler WF; Lam DSC;
Asia Pac J Ophthalmol (Phila); 2020; 9(2):85-87. PubMed ID: 32349115
[TBL] [Abstract][Full Text] [Related]
30. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Yahya AS; Khawaja S; Chukwuma J
Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32441496
[No Abstract] [Full Text] [Related]
31. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
Chen X; Geiger JD
Cell Signal; 2020 Sep; 73():109706. PubMed ID: 32629149
[TBL] [Abstract][Full Text] [Related]
32. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
33. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Biguetti C; Marrelli MT; Brotto M
Rev Saude Publica; 2020; 54():68. PubMed ID: 32638884
[TBL] [Abstract][Full Text] [Related]
34. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
Fassihi SC; Nabar NR; Fassihi R
Br J Pharmacol; 2020 Nov; 177(21):4997-4998. PubMed ID: 32562278
[No Abstract] [Full Text] [Related]
35. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
Chorin E; Dai M; Shulman E; Wadhwani L; Bar-Cohen R; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Chinitz LA; Jankelson L
Nat Med; 2020 Jun; 26(6):808-809. PubMed ID: 32488217
[No Abstract] [Full Text] [Related]
36. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Pani A; Lauriola M; Romandini A; Scaglione F
Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
[TBL] [Abstract][Full Text] [Related]
37. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
Chowdhury MS; Rathod J; Gernsheimer J
Acad Emerg Med; 2020 Jun; 27(6):493-504. PubMed ID: 32359203
[TBL] [Abstract][Full Text] [Related]
38. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
Pereira BB
J Toxicol Environ Health B Crit Rev; 2020 May; 23(4):177-181. PubMed ID: 32281481
[TBL] [Abstract][Full Text] [Related]
39. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Juurlink DN
CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
[No Abstract] [Full Text] [Related]
40. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
Borba MGS; Val FFA; Sampaio VS; Alexandre MAA; Melo GC; Brito M; Mourão MPG; Brito-Sousa JD; Baía-da-Silva D; Guerra MVF; Hajjar LA; Pinto RC; Balieiro AAS; Pacheco AGF; Santos JDO; Naveca FG; Xavier MS; Siqueira AM; Schwarzbold A; Croda J; Nogueira ML; Romero GAS; Bassat Q; Fontes CJ; Albuquerque BC; Daniel-Ribeiro CT; Monteiro WM; Lacerda MVG;
JAMA Netw Open; 2020 Apr; 3(4):e208857. PubMed ID: 32330277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
